HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
TerminatedNCT04821271

Antidepressant Effects of TS-161 in Treatment-Resistant Depression

Medication studyAges 18–65United States
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 65 years.

Listed locations
BethesdaSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: June 10, 2021
Recruitment status
Terminated
Enrollment listed in the registry
11
Sponsor
National Institute of Mental Health (NIMH)
Sponsor type
Government agency
Study type
Drug
Intervention type
Medication / drug, OTHER
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT04821271
Official title
Show the full official title

An Investigation of the Antidepressant Effects of the mGlu2/3 Receptor Antagonist TS-161 in Treatment-Resistant Depression

Recruitment & locations

Terminated

Bethesda

FAQ

Questions about this study

Who is behind this study?

The study sponsor is National Institute of Mental Health (NIMH), a government agency.

Does this study involve medication?

Yes. The study involves medication, including TS-161.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies